S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway

Progyny (PGNY) Stock Price, News & Analysis

$36.02
-0.50 (-1.37%)
(As of 03/1/2024 ET)
Today's Range
$35.63
$36.99
50-Day Range
$34.65
$41.62
52-Week Range
$29.44
$44.95
Volume
1.85 million shs
Average Volume
1.00 million shs
Market Capitalization
$3.45 billion
P/E Ratio
58.10
Dividend Yield
N/A
Price Target
$48.30

Progyny MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.1% Upside
$48.30 Price Target
Short Interest
Bearish
7.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Progyny in the last 14 days
Based on 52 Articles This Week
Insider Trading
Selling Shares
$10.75 M Sold Last Quarter
Proj. Earnings Growth
46.27%
From $0.67 to $0.98 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

138th out of 951 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

2nd out of 5 stocks


PGNY stock logo

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

PGNY Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript
Progyny Announces Share Repurchase Of Up To $100 Mln Of Common Stock
Progyny, Inc. Announces Share Repurchase Program
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Progyny (NASDAQ:PGNY) Shares Gap Down Following Analyst Downgrade
KeyBanc Reaffirms Their Buy Rating on Progyny (PGNY)
Progyny Inc.
Progyny, Inc. Announces Fourth Quarter 2023 Results
Progyny (NASDAQ:PGNY) Now Covered by Analysts at SVB Leerink
PGNY Mar 2024 40.000 put
See More Headlines
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/02/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
393
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$48.30
High Stock Price Target
$57.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+34.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$30.36 million
Pretax Margin
6.49%

Debt

Sales & Book Value

Annual Sales
$1.09 billion
Cash Flow
$0.66 per share
Book Value
$5.77 per share

Miscellaneous

Free Float
82,131,000
Market Cap
$3.45 billion
Optionable
Optionable
Beta
1.48

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PGNY shares.
View PGNY analyst ratings
or view top-rated stocks.

What is Progyny's stock price target for 2024?

10 equities research analysts have issued 1 year price targets for Progyny's shares. Their PGNY share price targets range from $43.00 to $57.00. On average, they anticipate the company's stock price to reach $48.30 in the next year. This suggests a possible upside of 34.1% from the stock's current price.
View analysts price targets for PGNY
or view top-rated stocks among Wall Street analysts.

How have PGNY shares performed in 2024?

Progyny's stock was trading at $37.18 on January 1st, 2024. Since then, PGNY shares have decreased by 3.1% and is now trading at $36.02.
View the best growth stocks for 2024 here
.

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PGNY earnings forecast
.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) issued its earnings results on Tuesday, February, 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. The firm earned $269.94 million during the quarter, compared to analysts' expectations of $274.08 million. Progyny had a net margin of 5.70% and a trailing twelve-month return on equity of 12.64%. The firm's quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 earnings per share.

What guidance has Progyny issued on next quarter's earnings?

Progyny issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.330-0.350 for the period, compared to the consensus estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.63%), International Assets Investment Management LLC (6.13%), Clearbridge Investments LLC (3.64%), Jennison Associates LLC (2.64%), Riverbridge Partners LLC (2.10%) and Riverbridge Partners LLC (1.91%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Michael E Sturmer, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 3/3/2024 by MarketBeat.com Staff